Usage Examples
- All subjects provided written informed consent before any screening procedure was performed.
- The ICF was amended and re-consent obtained at every site after the new hepatotoxicity signal.
- The IRB found and documented all five 21 CFR 50.22 criteria before approving the consent waiver.
What is Informed Consent (ICF)?
Informed Consent is the legally effective authorization a research subject gives before any study procedure, obtained under conditions that allow unhurried consideration, minimize coercion, and use language the subject actually understands.
Informed consent exists because a clinical investigation moves risk from a sponsor onto a person who is promised no benefit in return. FDA's answer is procedural rather than substantive: under 21 CFR 50.20 no investigator may involve a human being as a subject unless legally effective consent was obtained first, in language the subject understands, free of any exculpatory clause that waives the subject's legal rights.
Informed consent covers the entire exchange that precedes enrollment, not the signature at the end of it: the disclosure, the opportunity to consider, and the freedom to decline without penalty. Informed consent does not cover IRB review, protocol adequacy, or privacy authorization, and its reach stops at three exceptions written into 21 CFR Part 50 for minimal-risk waivers, life-threatening situations, and planned emergency research.
Informed consent is applied through an IRB-approved written form that the subject or the subject's legally authorized representative signs and dates at the time of consent, with a copy handed back to the signer. Informed consent also has a short-form path, where the elements are presented orally with a witness present and an IRB-approved written summary, used mainly for subjects who do not read the site's language.
Not to be confused with
- Informed Consent Form (ICF)
- the ICF is the document that records consent; informed consent is the authorization itself. A file of perfectly executed ICFs proves documentation, not that any subject understood what 21 CFR 50.20 requires them to understand.
- IRB approval
- an IRB approves the protocol and the consent form before the trial opens; informed consent is obtained from each individual subject afterwards. IRB approval never substitutes for a subject's consent, and the two obligations fail independently.
- The Common Rule (45 CFR Part 46)
- the Common Rule requires consent to begin with a concise, focused presentation of key information; FDA's 21 CFR 50.25(a) structures the same disclosure as a list of basic elements with no ordering requirement. A federally funded FDA-regulated trial is subject to both.
- Waiver (21 CFR 50.22) vs exception (21 CFR 50.24)
- a 50.22 waiver lets an IRB drop or alter consent for a minimal-risk investigation; a 50.24 exception permits enrollment without consent in planned emergency research and requires a licensed physician's concurrence. Different criteria, different documentation, not interchangeable.
The obligations below are the anchors an FDA inspector works from at a clinical site.
What you must do
- 1Obtain legally effective informed consent from the subject or the subject's legally authorized representative before involving any human being as a subject, under circumstances that give sufficient opportunity to consider participation and that minimize coercion or undue influence21 CFR 50.20
- 2Present the information in language understandable to the subject or representative, and strike any exculpatory language that waives the subject's legal rights or releases the investigator, sponsor, or institution from liability for negligence21 CFR 50.20
- 3Disclose the basic elements: that the study is research, its purpose and expected duration, the procedures and which are experimental, foreseeable risks, expected benefits, alternatives, confidentiality including possible FDA inspection of records, compensation and injury treatment, whom to contact, and that participation is voluntary21 CFR 50.25(a)
- 4Document consent on a written form approved by the IRB, signed and dated by the subject or representative at the time of consent, and give a copy to the person signing the form21 CFR 50.27(a)
- 5Before any consent waiver or alteration in a minimal-risk investigation, have the IRB find and document all five criteria, including that the investigation could not practicably be carried out without the waiver and that the waiver will not adversely affect subjects' rights and welfare21 CFR 50.22
- 6For federally conducted or supported research, open the consent with a concise and focused presentation of the key information most likely to help a prospective subject decide whether to participate45 CFR 46.116(a)(5)(i)
Common mistakes
Treating the signed ICF as the compliance artifact
21 CFR 50.20 conditions consent on understandable language, sufficient opportunity to consider, and absence of undue influence. None of those are evidenced by a signature. A form executed in eight minutes in a waiting room can be fully documented and still fail the standard, and the deficiency cannot be cured retroactively.
Consenting after the first study procedure
screening labs, washouts, and imaging performed before the form is signed are protocol deviations, and the data they produced is not usable. 21 CFR 50.27(a) fixes documentation at the time of consent, so correcting the date later converts one finding into two: an unconsented procedure and a falsified record.
Assuming a waiver is available because the study looks low-risk
21 CFR 50.22, added by FDA final rule 88 FR 88228 and effective 22 January 2024, requires the IRB to find and document all five criteria, one of which is that the investigation could not practicably be carried out without the waiver. Enrollment speed, cost, and site convenience are not impracticability, and a waiver granted on that reasoning does not hold up.
When This Matters
- All subjects provided written informed consent before any screening procedure was performed.
- The ICF was amended and re-consent obtained at every site after the new hepatotoxicity signal.
- The IRB found and documented all five 21 CFR 50.22 criteria before approving the consent waiver.
Frequently Asked Questions
The subject signs, or the subject's legally authorized representative signs when the subject cannot. Under 21 CFR 50.27(a) the written form must be approved by the IRB, signed and dated at the time of consent, and a copy given to the person signing. A witness signature is required only on the short-form path.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Clinical Workflows
Track clinical trial regulations across global markets
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
